Results for brain metastases and ROS1 resistance mutations
JIDEYTRO was shown to work against disease that had spread to the brain*
Results for people who had received 1 to 4 prior ROS1-targeted therapies
48% intracranial (in the brain) response rate
Intracranial duration of response
63% of people who responded
to treatment (15 out of 24) had results that lasted at least 12 months
Limitations of exploratory findings
Some study results, including the results above, are called exploratory. Exploratory findings look at additional questions beyond the main study goals. Because the results are from a small number of people, they should be interpreted carefully. These results may not reflect everyone’s experience.
*These people had measurable brain tumors when the clinical trial began and had not received radiation therapy to the brain within 2 months prior to study entry.
†At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.
‡A complete response (tumor disappearing) does not mean the cancer has been cured.
Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.
JIDEYTRO worked when ROS1+ NSCLC stopped responding to other treatments due to ROS1 resistance mutations
For people who had received 1 to 3 prior ROS1-targeted therapies and who had ROS1 resistance mutations
Resistance mutations are genetic changes in tumor cells that cause certain treatments to be less effective. They can be detected through biomarker testing during or following treatment.
Because participants had already tried between 1 and 3 ROS1-targeted treatments before JIDEYTRO, the results reflect how the therapy performed in people with advanced treatment histories.
*At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.
†A complete response (tumor disappearing) does not mean the cancer has been cured.
Individual treatment results may vary. Talk to your doctor to see if JIDEYTRO may be right for you.
Talk to your doctor to see if JIDEYTRO may be right for you.
Understanding the different ways results are measured
What is overall response rate?
The proportion of people who saw their tumors shrink by at least 30%* or disappear during treatment and follow-up in the clinical study. This includes both partial response and complete response.
What is partial response?
The cancer has shrunk by at least 30%,* and there are no signs that the cancer has grown anywhere else in the body.
What is complete response?
When signs of a tumor have completely disappeared with no evidence of disease visible on scans or other tests. This does not mean the cancer has been cured.
If cancer is in the brain, the results are measured by intracranial overall response rate, intracranial partial response, and intracranial complete response.
What is duration of response?
The length of time that a person keeps living without their cancer progressing, after seeing a complete response or partial response.
*At least a 30% decrease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) during 2 different tumor evaluations. RECIST is a standard way to measure how well a patient responds to treatment. It is based on whether tumors shrink, stay the same, get bigger, or spread to a new part of the body.
Learn how JIDEYTRO worked after 1 prior ROS1-targeted treatment.
How to take JIDEYTRO
Learn about taking once-daily JIDEYTRO, a medication that can coexist with your routine.
Download JIDEYTRO resources
Explore educational resources as you consider next steps.
NSCLC=non-small cell lung cancer; ROS1+=ROS proto-oncogene 1-positive.